<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>Isfahan University of Medical Sciences</PublisherName>
				<JournalTitle>Journal of Isfahan Medical School</JournalTitle>
				<Issn>1027-7595</Issn>
				<Volume>32</Volume>
				<Issue>320</Issue>
				<PubDate PubStatus="epublish">
					<Year>2015</Year>
					<Month>02</Month>
					<Day>20</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Effects of Resvin Supplement on the levels of Interleukin-6 and C-Reactive Protein and Insulin Resistance in Women with Type 2 Diabetes</ArticleTitle>
<VernacularTitle>Effects of Resvin Supplement on the levels of Interleukin-6 and C-Reactive Protein and Insulin Resistance in Women with Type 2 Diabetes</VernacularTitle>
			<FirstPage>2484</FirstPage>
			<LastPage>2490</LastPage>
			<ELocationID EIdType="pii">14549</ELocationID>
			
			
			<Language>FA</Language>
<AuthorList>
<Author>
					<FirstName>Ensiyeh</FirstName>
					<LastName>Yazdekhasti</LastName>
<Affiliation>Department of Sport Sciences, School of Humanities, Arak University, Arak, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Nader</FirstName>
					<LastName>Shavandi</LastName>
<Affiliation>Associate Professor, Department of Sport Sciences, School of Humanities, Arak University, Arak, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Ahmad</FirstName>
					<LastName>Mahmoudian</LastName>
<Affiliation>Associate Professor, Department of Community Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Abbas</FirstName>
					<LastName>Saremi</LastName>
<Affiliation>Assistant Professor, Department of Sport Sciences, School of Humanities, Arak University, Arak, Iran</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2015</Year>
					<Month>03</Month>
					<Day>19</Day>
				</PubDate>
			</History>
		<Abstract>Background: Inflammation increases the complications of diabetes mellitus. Antioxidants can reduce inflammation. Interleukin-6 (IL-6) and C-reactive protein (CRP) are inflammatory factors, and the question is whether the Resvin, as an antioxidant, can reduce the levels of both and impact on insulin resistance?Methods: In this semi-experimental study, with pre-test and post-test design, 16 women with type 2 diabetes were randomly assigned to two equal groups of intervention (mean age: 59.25 ± 5.11 years) and control (mean age: 52.25 ± 10.60 years). Subjects in the intervention group received 400 mg of Resvin supplements daily for 6 weeks. Blood samples were taken for determination of IL-6 and CRP levels and the insulin resistance, before and after the intervention.Finding: After 6 weeks of receiving Resvin supplementation, CRP and IL-6 levels significantly decreased in the intervention group (P &lt; 0.05). Insulin resistance improved significantly, too (P &lt; 0.05).Conclusion: Based on the findings, Resvin supplementation may reduce the inflammatory markers and insulin resistance in women with type 2 diabetes. </Abstract>
			<OtherAbstract Language="FA">Background: Inflammation increases the complications of diabetes mellitus. Antioxidants can reduce inflammation. Interleukin-6 (IL-6) and C-reactive protein (CRP) are inflammatory factors, and the question is whether the Resvin, as an antioxidant, can reduce the levels of both and impact on insulin resistance?Methods: In this semi-experimental study, with pre-test and post-test design, 16 women with type 2 diabetes were randomly assigned to two equal groups of intervention (mean age: 59.25 ± 5.11 years) and control (mean age: 52.25 ± 10.60 years). Subjects in the intervention group received 400 mg of Resvin supplements daily for 6 weeks. Blood samples were taken for determination of IL-6 and CRP levels and the insulin resistance, before and after the intervention.Finding: After 6 weeks of receiving Resvin supplementation, CRP and IL-6 levels significantly decreased in the intervention group (P &lt; 0.05). Insulin resistance improved significantly, too (P &lt; 0.05).Conclusion: Based on the findings, Resvin supplementation may reduce the inflammatory markers and insulin resistance in women with type 2 diabetes. </OtherAbstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Type 2 Diabetes</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Inflammation</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Insulin Resistance</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Resvin supplement</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://jims.mui.ac.ir/article_14549_d111f133fa0ea545d48291f9b0a72b2d.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
